№ files_lp_3_process_9_39180
File format: docx
Character count: 1041
File size: 208 KB
Note:
Year
Subject:
Veterinary medicine record
Document Type:
Record sheet
Context description:
A record sheet for documenting the purchase details of veterinary medicines.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Date:
20 August 2021
Version:
1.0
Document type:
User guide
Industry:
Aerospace industry
Topic:
Scope 3 greenhouse gas emissions
GHG scope:
Scope 3
Emission categories:
Purchased Goods & Services; Capital Goods
Methodological basis:
GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard
Organization:
International Aerospace Environmental Group (IAEG)
Working group:
IAEG Work Group 3
Purpose:
Voluntary accounting and reporting of greenhouse gas emissions
Geographical scope:
Aerospace industry value chain
Copyright holder:
International Aerospace Environmental Group (IAEG)
Status:
Informational document, not a standard
Approval date:
20 August 2021
Intended users:
Aerospace and defense companies and value chain partners
Period covered:
Not specified
Year:
2021
Region / City:
Rockville, MD
Topic:
340B Drug Pricing Program
Document Type:
Guidance
Organization / Institution:
Health Resources and Services Administration (HRSA)
Author:
Apexus
Target Audience:
340B stakeholders, covered entities, health departments
Effective Period:
Ongoing
Approval Date:
2021
Date of Changes:
N/A
Note:
Year
Subject:
Water System Review and Permitting
Document Type:
Checklist
Year:
2023
Region / City:
USA
Topic:
Cybersecurity Services, Risk Assessment, Vulnerability Testing
Document Type:
Template
Agency/Institution:
HACS
Author:
HACS
Target Audience:
Federal Agencies, Contractors
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2015
Region / City:
Czech Republic
Topic:
Reliability, Availability, Maintainability (RAM), Life Cycle Cost (LCC)
Document Type:
Instruction
Organization / Institution:
ŠKODA ELECTRIC a.s.
Author:
ŠKODA ELECTRIC a.s.
Target Audience:
Suppliers, Manufacturers
Validity Period:
Not specified
Approval Date:
14.11.2019
Revision Date:
14.11.2019
Change Description:
Updated address of ŠKODA ELECTRIC, minor changes in Chapter 4.1, added title in Chapter 4.2
Year:
2018
Region / City:
Tucson, AZ
Theme:
Food Safety, Product Recall
Document Type:
Recall Notice
Period of validity:
May 24, 2018
Date of approval:
May 25, 2018
Date of changes:
None
Context:
Recall notice issued for refrigerated products sold at a Fry’s Food Store due to temperature-related issues causing potential spoilage.
Year:
2026
Region:
United States
Topic:
Healthcare Claims Management
Document Type:
Guideline
Agency:
Veterans Affairs
Author:
Program Integrity Department
Target Audience:
Medical providers, healthcare facilities
Legal Reference:
31 U.S.C. 3729
Claim Types:
Purchased Care, CHAMPVA
Period of Application:
Ongoing
Date of Issue:
2026
Revision Date:
N/A
Content Focus:
Pre-payment claim scoring, rejection codes, overpayment recovery procedures
Year:
2024
Country:
South Africa
Institution:
National Assembly
Document type:
Parliamentary question and written reply
Question number:
597
Internal question paper number:
08
Publication date:
08 March 2024
Author of question:
Mr J N de Villiers (DA)
Responding authority:
Minister of Health
Government department:
Department of Health
Subject:
Government vehicle procurement for executive authorities
Reference question:
Question 86 replied to on 22 February 2023
Period covered:
8 May 2019 – 08 March 2024
Officials mentioned:
Dr MJ Phaahla, Dr ZL Mkhize, Dr S Dhlomo
Vehicle recorded:
Audi Q5 (2020)
Vehicle purchase date:
10 May 2020
Vehicle purchase price:
R 756,489.83
Type:
Evaluation form
Subject:
Textile and clothing assessment
Category fields:
Category number; Category name
Participant information:
Name (Last, First, Middle)
Affiliation:
Club/School
Award levels:
Blue; Red; White; No Award
Display compliance:
Displayed according to rules (Yes/No)
Evaluation criteria:
Selection and general appearance; Workmanship
Assessment items:
Overall appearance; Neat and clean; Pattern/fabric coordination; Color coordination; Article appropriate for intended use; Glues/adhesives are not visible; Trims/decorations properly attached; Decorations are appropriate and neat; Threads clipped
Scoring options:
Blue; Red; White; Needs Improvement
Additional notes:
Comments section included
Note:
Year
Type of Disinfectant:
Free chlorine / Chloramine
Minimum Residual:
0.2 mg/L for free chlorine, 0.5 mg/L for chloramine
Number of Customers:
Fewer than 750
Sampling Frequency:
Weekly for distribution system, monthly with coliform samples
Sample Count:
Up to 5 per worksheet
Data Recorded:
Sample date, sample site, disinfectant residual, below minimum, no residual
Reporting Form:
DLQOR
Purpose:
Monitoring disinfectant levels in small water systems
Year:
2023
Region / city:
Australia
Subject:
Pharmaceutical compounding guidelines
Document Type:
Guideline
Organization / Institution:
Pharmacy Board of Australia
Author:
Pharmacy Board of Australia
Target Audience:
Registered pharmacists, education providers, employers
Period of validity:
Indefinite
Approval Date:
Not specified
Date of amendments:
Not specified
Year:
2016
Region / City:
Australia
Topic:
Pharmacy, Medicine Compounding
Document Type:
Consultation Response
Organization:
Pharmaceutical Society of Australia
Author:
Dr Lance Emerson, Chief Executive Officer
Target Audience:
Pharmacists, Pharmacy Regulators
Period of Validity:
Indefinite
Approval Date:
1 February 2016
Date of Amendments:
None
Contextual Description:
Document is a public consultation response discussing terminology issues and proposed updates regarding compounded parenteral medicines, primarily aimed at Australian pharmacists.
Organisation:
Canberra Health Services
Document type:
Guideline
Reference number:
CHS25/225
Jurisdiction:
Australian Capital Territory
Healthcare setting:
Public health services
Subject area:
Medication management
Professional scope:
Nursing and midwifery practice
Approved by:
Drug and Therapeutics Committee
Target professionals:
Registered nurses and registered midwives
Patient groups:
Adults, children 12 years or older, and selected medicines for children under 12 years
Exclusions:
Neonates, Special Care Nursery patients, Neonatal Intensive Care Unit patients
Regulatory framework:
Australian medicines scheduling (Schedules 2, 3, 4, and 8)
Content components:
Governance, safe use, documentation, approved medicine lists
Year:
2023
Region / city:
European Union
Topic:
Pharmaceutical technology development
Document type:
Briefing document
Organization:
European Medicines Agency
Author:
Not specified
Target audience:
Pharmaceutical experts, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
This document is a briefing source for discussing pharmaceutical technology and regulatory aspects at a QIG 1:
1 meeting.
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Document type:
Q&A guidance
Jurisdiction:
Japan
Subject:
Import and shipment of medicines and medical devices
Issuing authority:
Ministry of Health, Labour and Welfare
Intended users:
Individuals importing or sending medicines for personal use
Scope:
Prescription medicines, injections, syringes, and medical devices
Import purpose:
Personal use
Regulatory framework:
Pharmaceutical and Medical Device regulations
Application system:
Online Import Confirmation system
Related forms:
Import Confirmation Application Form (Form 12); Explanation of Pharmaceutical Product (Form 13)
Year:
2024
Region / city:
Denmark
Topic:
Medicine, Health Economics
Document type:
Template
Organization / institution:
Danish Medicines Council
Author:
Danish Medicines Council
Target audience:
Pharmaceutical companies
Period of validity:
Ongoing
Approval date:
10 September 2024
Date of changes:
1 April 2025
Version:
2.5
Year:
2021
Region / city:
Victoria, Australia
Theme:
Pharmacist regulations
Document type:
Legislative guideline
Agency / institution:
Medicines and Poisons Regulation (MPR)
Author:
Medicines and Poisons Regulation (MPR)
Target audience:
Health practitioners, pharmacists
Period of validity:
Ongoing
Approval date:
2017
Date of amendments:
2021
Context:
This document provides guidelines for pharmacists regarding the dispensing, administration, and supply of Schedule 4 and 8 medicines in Victoria, Australia, as outlined in the Drugs Poisons and Controlled Substances Act 1981 and related regulations.